Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2007-01-09
2007-01-09
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S252700, C435S253600, C435S842000, C424S236100, C424S239100
Reexamination Certificate
active
11072050
ABSTRACT:
Animal product free (APF) media and processes for the culture and fermentation ofbotulinumtoxin producingClostridium botulinumbacteria. Thebotulinumtoxin obtained can be used for formulating and compoundingbotulinumtoxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.
REFERENCES:
patent: 6558926 (2003-05-01), Demain et al.
patent: 2003/0118598 (2003-06-01), Hunt et al.
patent: 2004/0235139 (2004-11-01), Demain et al.
patent: 2005/0238669 (2005-10-01), Xiang et al.
patent: WO 94/09115 (1993-10-01), None
patent: WO 98/54296 (1998-05-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01-36655 (2000-10-01), None
patent: WO 01/58472 (2001-02-01), None
patent: WO2005/035749 (2004-08-01), None
Naumann, M., et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,Euro. J. Neurology1999:6(Suppl 4):S111-S115.
Porfirio, Z., et al., Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin,J. of Applied Microbiology, 1997 83:678-684.
Ragona, Rosario Marchese, et al., Management of Parotid Sialocele with botulinum toxin,The Laryngoscope, 109:Aug. 1999:pp. 1344-1346.
Siegel, L.S., Fermentaton kinetics of botulinum toxin production (types A, B and E),Biomedical aspects of botulism, New York: Academic Press 1981:pp. 121-128.
Schantz, E.J., et al., Preparation and characterization of botulinum toxin type A for human treatment, Jankovic J, ed.;Neurological Disease and Therapy. Therapy withBotulinum Toxin, 1994;25:pp. 41-49.
Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine,Microbiological Reviews, Mar. 1992, p. 80-99.
Schiefer-Ullrich, H., et al., Comparative studies on physiology and taxonomy of obligatory purinolytic clostridia,Arch Microbiol, 1984, 138:345-353.
Whitmer, M.E., et al., Development of improved defined media forClostridium botulinumserotypes A, B and E,Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, p. 753-759.
Bonventre, P.F., et al., Physiology of toxin production byClostridium botulinumtypes A and B,College of Medicine, vol. 7, pp. 372-374, 1959.
Chen, F., et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component and the 900-kilodalton botulinum toxin complex species,Infect ImmunJun. 1998;66(6):2420-2425.
Holdeman, L., et al., A study of the nutritional requirements and toxin production ofClostridium botulinumtype F,Canadian Journal of Microbiology, vol. 11, (1965), pp. 1009-1019.
Johnson, E., et al.,Clostridium botulinumand its neurotoxins: a metabolic and cellular perspective,Toxicon39 (2001) 1703-1722.
Karasawa, T., et al., A defined growth medium for clostridium difficle,Microbiology(1995),141, 371-375.
Kohl, A., et al., Comparison of the effect of botulinum toxin A (BOTOX®) with the highly-purified neurotoxin (NT201) n the extensor digitorum brevis muscle test,MOV DISORD, 2000;15(Suppl 3):165.
Lewis, K.H., et al., Practical media and control measures for highly toxic cultures ofClostridium botulinumtype A,Production of Botulinum Toxin, pp. 213-230, 1947.
Li, Y., et al., Expression and characterization of the heavy chain of tetnus toxin: reconstitution of the fully-recombinant dichain protein in active form,J Biochem(Tokyo) Jun. 1999;125(6):1200-1208.
Heenan, C. N., et al., Lehensm.-Wiss. U.-Technol, 35 (2002), pp. 171-176.
Miwa, Norinaga, et al., International Journal of Food Microbiology, 49 (1999), pp. 103-106.
Mueller, J. H., et al., J. Bacteriology, Mar. 1954, 67(3), pp. 271-277.
Whitmer, M. E., et al., Applid and Environmental Microbiology, Mar. 1988, 54(3), pp. 753-759.
Oxoid—Product CM0149—product description, pp. 1-2, 2004.
Donovan Stephen
Wang Ping
Allergan Inc.
Donovan Stephen
Kam Chih-Min
LandOfFree
Media for clostridium bacterium and processes for obtaining... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Media for clostridium bacterium and processes for obtaining..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Media for clostridium bacterium and processes for obtaining... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774871